The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...

When evaluating 23andMe's stock performance and future outlook, investors should consider short-term market trends and long-term growth potential. This analysis will dive into recent stock metrics ...

Want to know more about your ancestry and heritage? In this year’s best Black Friday deals, DNA genetic testing kits from 23andMe are now 50% off, so shoppers can get insights into their health ...

Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company, after months of speculation about its future. The company's board has formed a ...

23andMe is not doing well. Its stock is on the verge of being delisted. It shut down its in-house drug-development unit last month, only the latest in several rounds of layoffs. Last week, the ...

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and ...

(JTA) — The genetic testing company 23andMe is facing a class action lawsuit over its security practices after hackers stole and published data about 1 million people with Jewish ancestry.

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses. The company that made its name by providing saliva ...

The genetic testing company 23andMe has agreed to pay $30 million to American plaintiffs to settle a lawsuit over a data breach last year that specifically targeted customers of Ashkenazi Jewish ...

23andMe (ME) stock nosedived over 33% yesterday after the board unanimously rejected CEO Anne Wojcicki’s takeover offer. The company has set up a Special Committee of the Board of Directors to ...

Anne Wojcicki is at it again. After a failed attempt to buy back the DNA testing company she cofounded, the CEO has made another offer to gain control of 23andMe. But if the sale goes through ...

Anna Wojcicki, the CEO of DNA testing app 23andMe that was sold for $6billion, is trying to buy the company back for just $75million. The troubled company was worth billions six years ago but now ...